How to better prepare patients for a cell or gene therapy trial

Parexel spoke with Doug Olson, Cancer survivor and CAR T-cell patient, about how healthcare providers and trial sponsors can better communicate with patients about CGTs.

Download PDF

Biotech Resources

How to better prepare patients for a cell or gene therapy trial

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Five competencies for operational excellence in cell and gene therapy clinical trials

Regulatory considerations from former FDA regulators

Payer insights for cell and gene therapies

Dosing strategies for gene therapies

CAR-T: A patient’s cell therapy success story

The Parexel Podcast | Episode 12: ASCO20 Debrief: The latest in cell and gene therapy

COVID-19 and the effect on cellular therapy trials

CMC Considerations for Gene Therapy and Regenerative Medicine Studies

Former FDA expert provides valuable advice on INTERACT programs for CBER products

Manufacturing Considerations for Cell and Gene Therapy Products to Mitigate the Risk of COVID-19 Disease Transmission

Establishing Manufacturing Controls: A Hurdle for the Cell and Gene Therapy Industry

Bioprocessing and Biologics risk from Coronavirus

CAR-T: How far have we come and where are we going?

How the UK's HTA Agency Uses Real-World Evidence to Develop Guidance

Beware of Regional Donor Eligibility Requirements: They're Not Really the Same Everywhere!

Demystifying FDA’s KASA Initiative… and how it aims to improve drug product, facility, and corporate quality monitoring

Commercializing Gene and Cellular Therapy

Criticality of Institutional Biosafety Committee for Clinical Studies of Cell and Gene Therapy Products

The State of Germline Gene Editing. What We Don’t Know!